Thrombocytopaenia is a known consequence of BCL-XL inhibition due to the absolute dependence of platelets on this pro-survival protein for their survival, and has hindered the translation of BH3-mimetics targeting BCL-XL to the clinic. The gene discussed is PROS1; the disease is Thrombocytopenia.